Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
Organogenesis Holdings Inc (ORGO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/08/2025: ORGO (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $7
1 Year Target Price $7
| 3 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -61.15% | Avg. Invested days 18 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/08/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 539.13M USD | Price to earnings Ratio - | 1Y Target Price 7 |
Price to earnings Ratio - | 1Y Target Price 7 | ||
Volume (30-day avg) 4 | Beta 1.64 | 52 Weeks Range 2.28 - 6.71 | Updated Date 07/8/2025 |
52 Weeks Range 2.28 - 6.71 | Updated Date 07/8/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.16 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -3.46% | Operating Margin (TTM) -23.28% |
Management Effectiveness
Return on Assets (TTM) 0.7% | Return on Equity (TTM) -4.92% |
Valuation
Trailing PE - | Forward PE 12.32 | Enterprise Value 596962528 | Price to Sales(TTM) 1.18 |
Enterprise Value 596962528 | Price to Sales(TTM) 1.18 | ||
Enterprise Value to Revenue 1.3 | Enterprise Value to EBITDA 30.88 | Shares Outstanding 126854000 | Shares Floating 55332244 |
Shares Outstanding 126854000 | Shares Floating 55332244 | ||
Percent Insiders 46.49 | Percent Institutions 51.84 |
Upturn AI SWOT
Organogenesis Holdings Inc
Company Overview
History and Background
Organogenesis Holdings Inc. was founded in 1985 and has evolved to focus on regenerative medicine, specializing in wound care and surgical biologics. It went public via SPAC in 2018.
Core Business Areas
- Advanced Wound Care: Focuses on providing advanced wound care products, including skin substitutes and wound dressings, used to treat chronic and acute wounds.
- Surgical & Sports Medicine: Develops and commercializes products for surgical and sports medicine applications, including products for orthopedic and soft tissue repair.
Leadership and Structure
The company is led by a CEO and a senior management team. The organizational structure includes departments for R&D, manufacturing, sales, marketing, and finance.
Top Products and Market Share
Key Offerings
- Apligraf: A bioengineered skin substitute for treating venous leg ulcers and diabetic foot ulcers. Market share data not publicly and readily available. Competitors include Mimedx, Integra LifeSciences.
- PuraPly AM: An antimicrobial barrier matrix used in wound management. Market share data not publicly and readily available. Competitors include Medline Industries, Smith+Nephew.
Market Dynamics
Industry Overview
The regenerative medicine and advanced wound care industry is experiencing growth due to the aging population, increasing prevalence of chronic diseases like diabetes, and advancements in biotechnology.
Positioning
Organogenesis is a key player in the advanced wound care market with a portfolio of innovative products. Its competitive advantage lies in its proprietary technologies and established sales channels.
Total Addressable Market (TAM)
The global wound care market is expected to reach over $25 billion. Organogenesis is positioned to capture a significant portion of this market through its advanced therapies.
Upturn SWOT Analysis
Strengths
- Innovative product portfolio
- Established sales channels
- Strong brand recognition in the wound care market
- Proprietary technologies
Weaknesses
- High operating expenses
- Reliance on third-party payers
- Limited diversification outside of wound care
Opportunities
- Expanding product portfolio through R&D
- Acquiring complementary businesses
- Increasing market penetration in international markets
- Developing new applications for existing products
Threats
- Increasing competition from other regenerative medicine companies
- Changes in reimbursement policies
- Potential product liability claims
- Economic downturn impacting healthcare spending
Competitors and Market Share
Key Competitors
- MIMD
- INTE
- BSX
- SNY
Competitive Landscape
Organogenesis is a significant player in the advanced wound care market with specialized products and strong market presence, but faces competition based on product offerings, pricing, and technological innovation.
Growth Trajectory and Initiatives
Historical Growth: Discuss Organogenesis Holdings Inc's growth trends over the past years using historical financial data.
Future Projections: Provide projections for Organogenesis Holdings Inc's future growth based on analyst estimates. Data is found through brokerage reports.
Recent Initiatives: Highlight recent strategic initiatives undertaken by Organogenesis Holdings Inc. using press releases and company reports
Summary
Organogenesis shows potential within the wound care market due to its innovative products and proprietary technologies. Its high operating expenses and reliance on third-party payers create vulnerabilities. Future growth depends on its ability to expand its portfolio and penetrate international markets, but must adapt to increasing competition and regulatory changes.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings (10-K, 10-Q), Press Releases, Market Research Reports, Analyst Estimates, publicly available information.
Disclaimers:
The data and analysis provided are for informational purposes only and should not be considered financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor. Market share estimates may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Organogenesis Holdings Inc
Exchange NASDAQ | Headquaters Canton, MA, United States | ||
IPO Launch date 2017-01-05 | President, CEO, Chair of the Board Mr. Gary S. Gillheeney Sr. | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 869 | Website https://organogenesis.com |
Full time employees 869 | Website https://organogenesis.com | ||
Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes products for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity and Novachor, which are amnion and chorion placental allografts for use in the care of chronic and acute wounds as protective barriers and extracellular matrix (ECM) scaffolds; Apligraf, a bioengineered bi-layered skin substitute for the treatment of venous leg ulcers and diabetic foot ulcers (DFU); Dermagraft, a dermal substitute grown from human dermal fibroblasts to treat DFUs; NuShield, a dehydrated placental allograft and surgical barrier to provide a protective barrier and ECM scaffold to support native healing; PuraPly Antimicrobial (AM) and PuraPly SX, which are antimicrobial barriers for the management of open wounds in surgical settings; and CYGNUS Dual, a dual-layered amniotic tissue graft used to treat chronic and acute wounds. It also provides PuraPly MZ, a micronized version of PuraPly for the management of open wounds in surgical settings; FortiShield, a biosynthetic wound matrix for use as a temporary protective covering; TransCyte, a bioengineered tissue scaffold that promotes burn healing; and PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications. In addition, the company develops ReNu, a cryopreserved suspension, which is in Phase 3 trial, for the management of symptoms associated with knee osteoarthritis; and placental products. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician offices through direct sales representatives and independent agencies. Organogenesis Holdings Inc. is headquartered in Canton, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.